Topotecan is indicated in the treatment of advanced-stage ovarian cancers refractory to prior platinum-based regimen. The aim of this study was to compare the standard therapeutic strategy with a novel strategy of weekly administration of topotecan. The primary endpoints were dose density and overall tolerance. This retrospective cohort study included patients with ovarian cancer in relapse. During a first period (1998–2001), 24 patients received the standard topotecan dose of 1.5 mg/m2/day for 5 consecutive days with a 3-week interval between each treatment course. During a second period (2003–2006), 21 patients received a weekly topotecan dose of 4 mg/m2 for 3 weeks out of every 4. Grades III and IV haematological toxicities were more frequent with the standard strategy (p < 0.05), even after adjustment of the prescription of erythropoietin and G-CSF. With the weekly strategy, an increase in dose density and a reduction in the number of delayed doses were observed. No significant difference between the 2 strategies was found in terms of response to the treatment and specific survival. This study suggests that the weekly administration of topotecan 4 mg/m2, for 3 weeks out of every 4, results in a better maintenance of dose density and a reduction in haematological toxicity.

1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics. CA Cancer J Clin 2007;57:43–66.
2.
Lasset C: Epidémiologie du cancer de l’ovaire; in Guastalla JP, Ray-Coquard I (eds): Les cancers ovariens. Collection Oncologie pratique. Paris, Springer, 2006, p 550.
3.
Cancer Research UK, Cancer Stats Ovarian Cancer-UK, 2004.
4.
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6.
5.
International Collaborative Ovarian Neoplasm (ICON): Group paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer. The ICON3 randomized trial. Lancet 2002;360:505–515.
6.
Blackledge G, Lawton F, Redman C, Kelly L: Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and design of phase III trials. Br J Cancer 1989;59:650–653.
7.
Fields AL, Runowicz CD: Current therapies in ovarian cancer. Cancer Invest 2003;21:148–156.
8.
Gore M, ten Bokkel Huinink W, Carmichael J, Gordon A, Davidson N, Coleman R, Spaczynski M, Heron JF, Bolis G, Malmstrom H, Malfetano J, Scarabelli C, Vennin P, Ross G, Fields SZ: Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 2001;19:1893–1900.
9.
Kudelka A, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ: Phase II study of intravenous topotecan as 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552–1557.
10.
Ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183–2193.
11.
Armstrong DK: Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002;7(suppl 5):20–28.
12.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone P: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
13.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.
14.
Crawford SM, Peace J: Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005;16:47–50.
15.
Morris RT, Alvarez RD, Malone J, Bryant C, Andrews SJ, Kilgore L, Phibbs GD, Heilbrun L, Munkarah AR: Phase II study of weekly topotecan in patients with relapsed platinum-sensitive ovarian or peritoneal cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23:5058.
16.
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0, 2003.
17.
Piccart MJ, Biganzoli L, Di Leo A: The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer 2000;36(suppl 1):S4–S10.
18.
Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V, Zee B: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16:2233–2237.
19.
Rodriguez M, Method MW, Lewandowski G, Vaccarello L, Ansari RH: A preliminary report of a phase II study of weekly topotecan in platinum-sensitive recurrent ovarian and peritoneal carcinoma. ASCO Annual Meeting Proceedings. J Clin Oncol 2004;23:5063.
20.
Safra T, Menczer J, Bernstein R, Shpigel S, Inbar MJ, Grisaru D, Golan A, Levy T: Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 2007;105:205–210.
21.
Bhoola SM, Estes JM, Leath CA 3rd, Kirby TO, Bunch P, Barnes MN 3rd, Patridge EE, Alvarez RD: Weekly topotecan is well tolerated in the third-line or later treatment of patients with epithelial ovarian carcinoma (EOC) and may prolong time to disease progression. ASCO Annual Meeting Proceedings. J Clin Oncol 2004;22:5067.
22.
Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95: 1–8.
23.
Chan S: Second-line chemotherapy for ovarian cancer. Lancet Oncol 2003;4:333–334.
24.
Blay JY, Koscielny S, Trédaniel J, Asselain B, Goldwasser F, Misset JL, de Labareyre C, Hagège C, Bismut H, Marty M: Rationale and delineation of a composite Index of Relative Antitumoural Efficacy (In-RATE). Crit Rev Oncol Hematol 2007;64:106–114.
25.
Ferrero J-M, Weber B, Geay J-F, Lepille D, Orfeuvre H, Combe M, Mayer F, Leduc B, Bourgeois H, Paraiso D, Pujade-Lauraine E: Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007;18:263–268.
26.
National Institutes of Health: Caelyx plus carboplatin versus paclitaxel plus carboplatin in patients with epithelial ovarian cancer in late relapse. http://clinicaltrials.gov/ct/show/NCT00189553.
27.
Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO: Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006;98:1036–1045.
28.
Stathopoulos GP, Malamos NA, Aravantinos G, Rigatos S, Christodoulou C, Stathopoulos J, Skarlos D: Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer Chemother Pharmacol 2007;60:123–128.
29.
National Institutes of Health: Taxol® in monotherapy or in combination with topotecan or carboplatin in patients with epithelial ovarian cancer in early relapse. http://clinicaltrials.gov/ct/show/NCT00189566.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.